AU2022205648A1 - Combination therapy using an anti-fucosyl-gm1 antibody - Google Patents

Combination therapy using an anti-fucosyl-gm1 antibody Download PDF

Info

Publication number
AU2022205648A1
AU2022205648A1 AU2022205648A AU2022205648A AU2022205648A1 AU 2022205648 A1 AU2022205648 A1 AU 2022205648A1 AU 2022205648 A AU2022205648 A AU 2022205648A AU 2022205648 A AU2022205648 A AU 2022205648A AU 2022205648 A1 AU2022205648 A1 AU 2022205648A1
Authority
AU
Australia
Prior art keywords
seq
antibody
sequence
fucosyl
gml
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022205648A
Other languages
English (en)
Other versions
AU2022205648A9 (en
Inventor
Yu Liu
Sarah TANNENBAUM-DVIR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2022205648A1 publication Critical patent/AU2022205648A1/en
Publication of AU2022205648A9 publication Critical patent/AU2022205648A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022205648A 2021-01-08 2022-01-07 Combination therapy using an anti-fucosyl-gm1 antibody Pending AU2022205648A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163135479P 2021-01-08 2021-01-08
US63/135,479 2021-01-08
PCT/US2022/011564 WO2022150557A1 (en) 2021-01-08 2022-01-07 Combination therapy using an anti-fucosyl-gm1 antibody

Publications (2)

Publication Number Publication Date
AU2022205648A1 true AU2022205648A1 (en) 2023-08-24
AU2022205648A9 AU2022205648A9 (en) 2024-09-19

Family

ID=80119207

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022205648A Pending AU2022205648A1 (en) 2021-01-08 2022-01-07 Combination therapy using an anti-fucosyl-gm1 antibody

Country Status (10)

Country Link
US (1) US20240050564A1 (https=)
EP (1) EP4274850A1 (https=)
JP (1) JP2024503379A (https=)
KR (1) KR20230129467A (https=)
CN (1) CN116745322A (https=)
AU (1) AU2022205648A1 (https=)
CA (1) CA3204392A1 (https=)
IL (1) IL304200A (https=)
MX (1) MX2023007780A (https=)
WO (1) WO2022150557A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201912657D0 (en) * 2019-09-03 2019-10-16 Scancell Ltd Binding members

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
US8383118B2 (en) 2005-12-08 2013-02-26 Medarex, Inc. Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US11104739B2 (en) * 2016-04-14 2021-08-31 Bristol-Myers Squibb Company Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody
CN109475634A (zh) * 2016-06-03 2019-03-15 百时美施贵宝公司 用于治疗复发性小细胞肺癌的方法的抗-pd-1抗体
RU2765997C2 (ru) * 2017-03-30 2022-02-07 Мерк Патент Гмбх Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования
MY205645A (en) * 2018-06-23 2024-11-02 Genentech Inc Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor

Also Published As

Publication number Publication date
IL304200A (en) 2023-09-01
WO2022150557A1 (en) 2022-07-14
EP4274850A1 (en) 2023-11-15
JP2024503379A (ja) 2024-01-25
CA3204392A1 (en) 2022-07-14
MX2023007780A (es) 2023-07-10
KR20230129467A (ko) 2023-09-08
AU2022205648A9 (en) 2024-09-19
US20240050564A1 (en) 2024-02-15
CN116745322A (zh) 2023-09-12

Similar Documents

Publication Publication Date Title
US20200197518A1 (en) Compositions comprising a combination of an anti-pd-1 antibody and another antibody
KR102515509B1 (ko) 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
TWI795347B (zh) 使用抗ｐｄ-１抗體與抗ｃｔｌａ-４抗體之組合以治療肺癌
SG10202111905PA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
US20250361313A1 (en) Combination therapy using an anti-fucosyl-gm1 antibody and an anti-cd137 antibody
KR20170007750A (ko) Ｈｐｖ-음성 암의 치료를 위한 ｐｄｌ-1의 길항제 및 ｐｄ-1의 길항제
JP2020520912A (ja) 抗ｇｉｔｒアゴニスト抗体での癌の処置
AU2021271971A1 (en) Compositions and methods for treating cancer
WO2020007368A1 (zh) 低adcc/cdc功能性单抗及其制备方法与应用
AU2016317378B2 (en) Agent for enhancing immunity to cancer by using Allergin-1 antagonist
KR20250004508A (ko) 암의 치료를 위한 조합 요법
US20240050564A1 (en) Combination therapy using an anti-fucosyl-gm1 antibody
KR20240038769A (ko) 항-ilt3 항체를 사용하여 급성 골수성 백혈병을 치료하는 방법
TW202502813A (zh) 包含偶聯物的藥物組合的治療方法和用途
CN113365659B (zh) 抗pd-l1抗体治疗头颈癌的用途
EA049752B1 (ru) Комбинированная терапия с применением анти-фукозил-gm1 антитела
AU2007299582B2 (en) Anti-cancer antibodies against Lewisy and Lewisb antigens
WO2025036445A1 (en) Treatment of lung cancer with anti-pd-1 and chemotherapy
WO2020063433A1 (zh) 抗程序性死亡配体-1(pd-l1)抗体的抗肿瘤用途
WO2020049534A1 (en) Sting agonist and combination therapy thereof for the treatment of cancer
TW202523693A (zh) 手術前後基於抗ｐｄ－１之治療
KR20260054704A (ko) 항-pd-1 및 화학요법을 이용한 폐암 치료
TW202400656A (zh) 使用ctla-4及pd-1雙特異性抗體之治療方法
TW202502382A (zh) 治療組合及其用途和治療方法
HK40117614A (zh) 使用ctla-4和pd-1双特异性抗体的治疗方法

Legal Events

Date Code Title Description
SREP Specification republished